QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 专题：合肥物质科学研究院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens 期刊论文 JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021 作者:  Cao, Fei;  Zheng, Jiaping;  Luo, Jun;  Zhang, Zhewei;  Shao, Guoliang 收藏  |  浏览/下载：47/0  |  提交时间：2021/08/30 Regorafenib plus DEB-TACE  CRLM  Treatment response  Prognosis  Adverse events   A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer 期刊论文 CHINESE JOURNAL OF CANCER RESEARCH, 2016, 卷号: 28 - 收藏  |  浏览/下载：7/0  |  提交时间：2020/10/26 METASTATIC COLORECTAL-CANCER  1ST-LINE TREATMENT  ADJUVANT CHEMOTHERAPY  PATHOLOGICAL RESPONSE  LIVER METASTASES  STAGE-II  OXALIPLATIN  FLUOROURACIL  LEUCOVORIN  IRINOTECAN  5-Fluorouracil  colon cancer  irinotecan  oxaliplatin  neoadjuvant  chemotherapy   Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma 期刊论文 WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 卷号: 15 - 收藏  |  浏览/下载：7/0  |  提交时间：2020/10/26 COLORECTAL LIVER METASTASES  TEMPERATURE DISTRIBUTION  HEPATIC CRYOSURGERY  ARTERIAL CHEMOEMBOLIZATION  ABLATION  COMPLICATIONS  CRYOABLATION  CRYOTHERAPY  RESECTION  TUMORS  Hepatocellular carcinoma  Cryosurgery  Transarterial chemoembolization  Cryoablation  Treatment   Analysis of risk factors for the interval time, number and pattern of hepatic metastases from gastric cancer after radical gastrectomy 期刊论文 WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 卷号: 14 - 收藏  |  浏览/下载：7/0  |  提交时间：2020/10/26 LIVER METASTASES  PROGNOSTIC-FACTORS  SUBTOTAL GASTRECTOMY  CURATIVE RESECTION  COLORECTAL-CANCER  CARCINOMA  ADENOCARCINOMA  CLASSIFICATION  RECURRENCE  SURVIVAL  gastric cancer  gastrectomy  hepatic metastasis  risk factor